pharma · Coronary Artery Bypass Grafting · Hypertension Pulmonary Secondary · TENX
TENAX THERAPEUTICS
TENAX THERAPEUTICS, INC.
TENAX THERAPEUTICS clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Chapel Hill, USA
- Employees
- 19
- Programs
- 7
- Drugs
- 2
- Patents
- 4
TENAX THERAPEUTICS projects
4 ClinicalTrials.gov programs sponsored by TENAX THERAPEUTICS.
TENAX THERAPEUTICS has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Levosimendan
TENAX THERAPEUTICS, INC.
Coronary Artery Bypass Grafting
1 trial -
TNX-103
TENAX THERAPEUTICS, INC.
Pulmonary Hypertension
1 trial -
TNX-103
TENAX THERAPEUTICS, INC.
Pulmonary Hypertension Associated With HFpEF
2 trials -
TNX-103-07
TENAX THERAPEUTICS, INC.
Pulmonary Hypertension (PH) with Heart Failure with preserved left ventricular ejection fraction (PH-HFpEF)
1 trial
Frequently asked questions
How many clinical projects does TENAX THERAPEUTICS have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.